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PKCParathyroid hormone (PTH) functions as a major mediator of bone remodeling and as an essential
regulator of calcium homeostasis. In this study, we investigated the role of PTH in the regulation of the cell
cycle in human colon adenocarcinoma Caco-2 cells. Flow cytometry analysis revealed that PTH (10−8 M,
12–24 h) treatment increases the number of cells in the G0/G1 phase and diminishes the number in both
phases S and G2/M. In addition, analysis by Western blot showed that the hormone increases the
expression of the inhibitory protein p27Kip1 and diminishes the expression of cyclin D1, cyclin D3 and
CDK6. However, the amounts of CDK4, p21Cip1, p15INK4B and p16INK4A were not different in the absence
or presence of PTH. Inhibitors of PKC (Ro-318220, bisindolylmaleimide and chelerythine), but not JNK
(SP600125) and PP2A (okadaic acid and calyculin A), reversed PTH response in Caco-2 cells. Taken
together, our results suggest that PTH induces G0/G1 phase arrest of Caco-2 intestinal cells and changes the
expression of proteins involved in cell cycle regulation via the PKC signaling pathway.ica & Farmacia, Universidad
a, Argentina. Tel.: +54 291
d).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Proliferation of eukaryotic cells depends on progression through
the cell cycle, and cell cycle control is achieved through the actions of
a family of cyclin-dependent protein kinases (CDKs) and cyclins that
initiate phosphorylation events to allow progression through check-
points in the cell cycle. In mammalian cells, progression through the
G1 phase requires, early in G1, the activity of the cyclin D-dependent
kinases CDK4 and/or CDK6 and, later in G1, the cyclin E-dependent
kinase CDK2. G1 kinases can be regulated by changes in cyclin levels
or CDK activity and by a CDK-activating kinase (CAK) [1]. Two families
of CDK inhibitors (CDKIs) are critical mediators of anti-proliferative
signals that arrest the cell cycle. Cip/Kip family includes p21Cip1 (also
known as WAF1, Sdi1, and CAP20), p27Kip1, and p57Kip2 whereas
INK4 family includes p16INK4A, p15INK4B, p18INK4C, and p19INK4D.
These inhibitors negatively regulate G1 phase progression by forming
complexeswith CDKs and thus preventing S phase entry [2,3]. In vitro,
p21Cip1, p27Kip1, and p57Kip2 inhibit a wide variety of cyclin-CDK
complexes, including cyclin D-CDK4/6 and cyclin A/E-CDK2. Ink4
inhibitors are speciﬁc for CDK4 and CDK6 and interfere with cyclin D
binding to these kinases.
Parathyroid hormone (PTH) is amajormediator of bone remodeling
and an essential regulator of calcium homeostasis. Very small
decrements in serum calcium levels induce the secretion of PTH fromtheparathyroidglands initiating a rapid response to raise serumcalcium
levels by acting directly on kidney and bone or indirectly on intestine
(via 1,25(OH)2 vitamin D3) facilitating calcium absorption [4,5].
Mammalian PTH is an84-aminoacid single-chainpolypeptide, although
only theﬁrst 34 aminoacids are required formostbiological effects [6,7].
The PTH receptor (PTH1R) is highly expressed in bone and kidney, but is
found also in a variety of tissues not regarded as classical PTH target
tissues, including intestinal cells [8–10]. PTH binds to its receptor and
activates at least two signal transduction systems: the cAMP-dependent
protein kinase (PKA) [11,12] and the phospholipase C-activated
calcium/protein kinase C (Ca2+/PKC) pathways [11,13].
Depending on the experimental conditions, PTH also can inhibit
or promote proliferation and induces alterations in cell cycle
regulation [14,15].
Using the human colon cell line Caco-2 we previously obtained
evidence that PTH diminishes the number of viable cells, induces
morphological changes typical of apoptotic cells [10] and activates
several pro-apoptotic factors [16]. However, the role of PTH in the
proliferation of Caco-2 cells remains understood. The present study
was designed to explore if PTH regulates the cell cycle progression in
these colon cancer cells and to investigate the mechanisms that are
involved in this process.
2. Materials and methods
2.1. Materials
Human PTH (1–34) was obtained from Calbiochem (San Diego, CA,
USA). High glucose Dubelcco's modiﬁed Eagle's medium (DMEM)was
from Sigma Chemical Co. (St. Louis, MO, USA). Fetal bovine serum
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the following sources: anti-cyclin D1, anti-cyclin D3, anti-CDK4, anti-
CDK6, anti-p27Kip1, anti-p21Cip1, anti-p15Ink4B, anti-p16Ink4A,
were from Cell Signaling Technology (Beverly, MA, USA). Goat anti-
rabbit peroxidase-conjugated secondary antibody and goat anti-
mouse peroxidase-conjugated secondary antibody were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-actin antibody,
bisindolylmaleimide (BIM), chelerythine, okadaic acid sodium and
calyculin A were from Sigma (Sigma Chemical Co. St. Louis, MO, USA).
Ro-31-8220 was from Calbiochem (San Diego, CA, USA). SP600125
was obtained from Tocris Cookson Inc. (Ellisville, MO, USA). RNase
Cocktail™ Enzime Mix was from Applied Biosystems (Carlsbad,
California). Propidium iodide (PI) was from Invitrogen (Carlsbad,
California). Protein size markers were from Amersham Biosciences
(Piscataway, NJ, USA), and PVDF (Immobilon polyvinylidene diﬂuor-
ide) membranes and ECL chemiluminescence detection kit were from
Amersham (Little Chalfont, Buckinghamshire, England). All other
reagents used were of analytical grade.
2.2. Cell culture and treatment
The human colon cell line Caco-2 (from the American Tissue
Culture Bank (Bethesda, USA)) was cultured at 37 °C in DMEM
containing 10% FBS, 1% non-essential acids, 100 UI/ml penicillin,
100 mg/ml streptomycin and 50 mg/ml gentamycin in a humid
atmosphere of 5% CO2 in air. Cultures were passaged every 2 days
with fresh medium. Experimental cultures were grown to 50–70%
conﬂuence in serum-containing medium, and then cells were serum
deprived 24 h before the addition of PTH (10−8 M) in DMEM
containing 2% FBS for 3, 6, 14 or 24 h. Where indicated, cells were
pretreated for 30 min with Ro-31-8220, bisindolylmaleimide (BIM),
chelerythine, okadaic acid sodium, calyculin A or SP600125. The
inhibitors were present during subsequent exposure to the hormone.
2.3. Cell cycle analysis
Cell cycle distribution was analyzed by ﬂow cytometry. Cells
incubated with or without PTH for 12 or 24 h were trypsinized,
washed once with PBS, and ﬁxed in 70% ethanol for at least 1 h at
−20 °C. Fixed cells were washed with PBS and incubated with
propidium iodide (PI) staining solution (69 μM IP, 38 mM sodium
citrate and 0.7 mg/ml ribonuclease A, pH 7.4) for 30 min at 37 °C in
the dark. The stained cells were analyzed by FACSCalibur ﬂow
cytometer (Becton Dickinson). The program used for the acquisition
and analysis of the samples was the CellQuest.
2.4. Western blot analysis
Caco-2 cells were washed with PBS buffer plus 25 mM NaF and
1 mM Na3VO4, and lysed in buffer containing 50 mM Tris–HCl (pH
7.4), 150 mM NaCl, 3 mM KCl, 1 mM EDTA, 1% Tween-20, 1% Nonidet
P-40, 20 μg/ml aprotinin, 20 μg/ml leupeptin, 1 mM phenylmethyl-
sulfonyl ﬂuoride (PMSF), 25 mM NaF and 1 mM Na3VO4. The lysates
were incubated on ice for 10 min, vortexed for 45 s andmaintained on
ice for another 10 min. After centrifugation at 14,000×g and 4 °C
during 15 min the supernatant was collected and proteins were
quantiﬁed by the Bradford method [17]. Lysate proteins dissolved in
6× Laemmli sample buffer were separated (25 μg/lane) using SDS-
polyacrylamide gels (10% or 15% acrylamide) and electrotransfered to
PVDF membranes. After blocking with 5% non-fat milk in TBST buffer
(50 mM Tris pH 7.2–7.4, 200 mM NaCl, 0.1% Tween-20), the
membranes were incubated overnight with the appropriate dilution
of primary antibody in TBST with 1% non-fat milk. After washing,
membranes were incubated with the appropriate dilution of horse-
radish peroxidase-conjugated secondary antibody in TBST with 1%
non-fat milk. Finally, the blots were developed by ECL with the use ofKodak BioMax Light ﬁlm and digitalized with a GS-700 Imaging
Densitomer (Bio-Rad, Hercules, CA, USA).
2.5. Stripping and reprobing membranes
The complete removal of primary and secondary antibodies from
the membranes was achieved by incubating the membranes
in stripping buffer (62.5 mM Tris–HCl pH 6.8, 2% SDS and 50 mM
β-mercaptoethanol) at 55 °C for 30 min with agitation. Then,
membranes were washed for 10 min in TBST (1% Tween-20) and
blocked, as indicated above, for 1 h at room temperature. After that,
membranes were ready to reprobewith the corresponding antibodies.
2.6. Statistical analysis
The statistical signiﬁcance of the data was evaluated using
Student's t test, and probability values below 0.050 (pb0.050) were
considered signiﬁcant. Quantitative data are expressed as means±SD
from the indicated set of experiments.
3. Results
Initial experiments were performed to investigate the effect of PTH
on theprogression of the cell cycle in Caco-2 cells. To that end, cellswere
incubated with or without PTH (10−8 M) for 12 and 24 h and the
percentages of cells in the G0/G1, S, and G2/M phases were determined
by ﬂow cytometric analysis of propidium iodide stained cells as
described in Materials and methods. As shown in Fig. 1 the hormone
increased the percentage of cells in G0/G1 from 55.9% to 66.9%
(pb0.025) and 67.5% to 73.9% (pb0.01) at 12 and 24 h, respectively,
which was accompanied by a corresponding reduction in the percent-
age of cells in S phase from 33.1% to 20.7% (pb0.01) and 17.4% to 15%
(pb0.025) at 12 and 24 h, respectively. These data suggest that PTH
induces cell cycle arrest at G0/G1 phase in Caco-2 cells.
We next analyzed whether the cell cycle arrest at G0/G1 phase by
PTH was related to changes in the expression of cell cycle-regulatory
proteins that are essential for cell cycle progression from G1 to S
phase. To that end, Caco-2 cells were treated with or without PTH
(10−8 M) for 3–24 h followed by immunoblot analysis using speciﬁc
antibodies. As demonstrated in Fig. 2, PTH markedly diminished the
expression of cyclin D1, cyclin D3 and CDK6, which are responsible for
cell cycle progression in the early G1 phase, whereas CDK4 levels were
unaffected by PTH treatment. In order to evaluate the equivalence of
protein content among the different experimental conditions, blotted
membranes were re-probed with anti-β-actin antibody. To further
clarify the mechanism of PTH-induced G0/G1 cell cycle arrest and,
since cell cycle progression is also controlled by speciﬁc CDK
inhibitors (INK4 and Cip/Kip family), we evaluated the expression of
p16INK4A, p15INK4B, p27Kip1 and p21Cip1 after PTH treatment for 3
to 24 h. In Fig. 3A and B, Western blot analysis show that the hormone
increased the expression of the inhibitory protein p27Kip1. However,
the amounts of p21Cip1, p15INK4B and p16INK4A were not different
in the absence or presence of PTH. Taken together, these results reveal
that PTH (10−8 M) arrests the cell cycle by up-regulation of p27Kip1
expression and down-regulation of cyclin D1, cyclin D3 and CDK6
expressions. The expressions of these cell cycle-regulatory proteins
were not affected when Caco-2 cells were treated with concentrations
of PTH lower and higher than 10−8 M (data not shown).
It has been demonstrated that signaling through c-jun N-terminal
kinases (JNKs) regulates cell cycle control and the induction of
apoptosis [18,19]. Previously, Grösch S. et al. [20] showed that S-
ﬂurbiprofen, an unselective cyclooxygenase inhibitor, and its inactive
enantiomer inhibit the proliferation of Caco-2 cells through G1-cell
cycle blockade associated with an activation of JNK, an increase of the
DNA binding activity of the transcription factor AP-1 and down-
regulation of cyclin D1 expression. Therefore, to gain insight into the
Fig. 1. Effect of PTH on cell cycle progression. Caco-2 cells were incubated in serum-free DMEM for 24 h and then treated with or without PTH (10−8 M, in DMEM 2% FBS) for 12 and
24 h. Cells were then stained with propidium iodide and the distribution of cells in the cell cycle was analyzed by ﬂow cytometry of DNA content. Representative cytometric proﬁles
and percentage of each phase are shown. The program CellQuest was used for acquisition and analysis the FACS scans. Data represents mean±SD of three independent experiments.
G0/G1=cells in G0/G1 cell cycle phases; S=cells in S cell cycle phase; G2/M=cells in G2/M cell cycle phases.
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Caco-2 cells were pre-incubatedwith JNK inhibitor SP600125 (20 μM)
for 30 min and then treated with PTH (10−8 M, 6 h). As shown in
Fig. 4, the inhibition of JNK activity did not reverse hormone response,
suggesting that the effect of PTH on the expression of cyclin D1, cyclin
D3 and CDK6 is independent of the JNK pathway.It has been shown that protein phosphatase 2A (PP2A) mediates
the down-regulation of cyclin D1 in the intestinal crypt cells IEC-18
[21]. Since we previously reported that PTH induced PP2A activation
in Caco-2 cells [22], we also investigated the role of PP2A in the
regulation of PTH-induced cell cycle arrest. To that end, cells were
pre-treated with the phosphatase inhibitors okadaic acid (OA) at a
Fig. 2. PTH diminishes the expression of cyclin D1, cyclin D3 and CDK6. Caco-2 cells were incubated in serum-free DMEM for 24 h and then treated with or without PTH (10−8 M, in
DMEM 2% FBS) for 3, 6, 14 and 24 h. Proteins from lysates were prepared as described in Materials and methods, separated on 15% SDS-PAGE, and immunoblotting using (A) anti-
cyclin D1 or anti-CDK4 antibodies; (B) anti-cyclin D3 or anti-CDK6 antibodies. In order to evaluate the equivalence of protein content among the different experimental conditions,
blotted membranes were reprobed with anti-β-actin antibody. (C) Densitometric analyses were performed on the anti-cyclin D1, anti-cyclin D3 and anti-CDK6 immunoblots from
three independent experiments; means±SD are given. *Pb0.05, **Pb0.025, ***Pb0.01 with respect to the corresponding control.
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then incubated with PTH (10−8 M, 6 h). Inhibition of PP2A did not
reverse hormone-mediated down-regulation of cyclin D1, cyclin D3
and CDK6, suggesting that the effect of PTH on the expression of these
cell cycle regulatory proteins is independent of the PP2A pathway
(Fig. 4 A and B).
PKC is a member of serine/threonine kinase whose isoforms have
been shown to be involved in a number of cellular processes. Several
studies implicate PKC isozymes in either positive or negative
regulation of G1-S progression, via alterations in the expression of
cyclins and/or CDK inhibitors andmodulation of the activity of speciﬁc
cyclin-CDK complexes [23,24]. In attempt to investigate whether the
PKC pathway is involved in PTH-induced cell cycle arrest, PKC
inhibitors Ro-31-8220, (200 nM); BIM (5 μM) and chelerythrine,
(2 μM), were added before the cells were treated with PTH followedby immunoblot analysis using speciﬁc antibodies. As shown in Fig. 5,
PKC inhibitors prevented PTH-induced downregulation of cyclin D1,
cyclin D3 and CDK6. Moreover, p27Kip1 protein level signiﬁcantly
decreasedwhen Caco-2 cells were incubated with Ro-31-8220, BIM or
chelerythrine followed by PTH treatment for 24 h (Fig. 6).
These ﬁndings indicate that PTH regulation of cyclin D1, cyclin D3,
CDK6 and p27Kip1 are PKC dependent in Caco-2 cells.
4. Discussion
The results of the present investigation provide, to our knowledge,
the ﬁrst direct evidence demonstrating that PTH induces G0/G1 cell
cycle arrest in Caco-2 cells. Many reports have shown that PTH
inhibits or promotes cell cycle progression, depending on the
experimental conditions and cell type. PTH stimulates the progression
Fig. 3. PTH increases p27Kip1 expression. Caco-2 cells were treated as described in the
legend of Fig. 2. Immunoblots were performed using (A) anti-p27Kip1 or anti-
p16INK4A antibodies; (B) anti-p21Cip1 or anti-p15INK4B antibodies. In order to
evaluate the equivalence of protein content among the different experimental
conditions, blotted membranes were reprobed with anti-β-actin antibody.
(C) Densitometric analyses were performed on the anti-p27Kip1 immunoblots from
three independent experiments; means±SD are given. *Pb0.025 with respect to the
corresponding control.
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expression and its activity through the actions of the E2F transcription
factor in the human osteosarcoma cell line TE-85 [25]. The hormone
also induces the expression of cyclin D1 in early osteoblastic cells [14]
and, in chondrocytes and chondrosarcoma cells, an activating
mutation of the PTH receptor (PTH1R) causes an increase in cyclin
D1 and cyclin A expression [26]. However, PTH is known to inhibit cell
cycle progression in the UMR-106 cell line, a relatively differentiated
osteoblastic osteogenic sarcoma line, by increasing p27Kip1 levels and
inhibiting CDK2 activity, which are mediated through the protein
kinase A pathway [27]. In addition, Qin L. et al. [15], showed that PTH
inhibits the growth of osteoblastic cell lines, arresting them in G1
phase by inducing the expression of both, MAPK phosphatase 1
(MKP-1) and p21Cip1 and by decreasing cyclin D1 expression.
Previous studies in our laboratory, using the human colon cell line
Caco-2, demonstrated that PTH decreases the number of viable cells
[10]. However, at the moment the effects that PTH exerts on the cell
cycle in these cells were unknown. Therefore, we ﬁrst analyzed the
DNA contents by ﬂow cytometry in Caco-2 cells, and we found that
PTH increases the number of cells in the G0/G1 phase and diminishes
the number of cells in S phase.
It has been well documented that cell cycle is primarily regulated
by complexes containing CDKs and cyclins, which are critical for
progression of cell cycle and their inactivation leads to cell cycle arrest[28,29]. The complexes responsible for the progression of cells
through the G1 phase of cell cycle and the initiation of DNA replication
include cyclin D-CDK4/CDK6 and cyclin E-CDK2 [30]. Aberrant
proliferation of cancer cells involves the deregulation of key G1
phase cell cycle regulators, and overexpression of cyclins and CDKs
provides a selective growth advantage to tumor cells [31]. Therefore,
targeting cyclin-CDK complexes that promote tumor progression is
therapeutically relevant for the treatment of cancer. Our results
showed that PTH treatment caused a decrease in the protein levels of
CDK 6, cyclin D1, and cyclin D3, explaining the plausible role of these
cell cycle regulatory proteins, in the PTH-induced G0/G1 arrest
observed in Caco-2 intestinal cells.
p27Kip1 is a negative regulator of the cell cycle and a potential
tumor suppressor gene as well as a promoter of apoptosis [32–34].
p27Kip1 expression, that is primarily increased in response to
extracellular anti-mitogenic signals for cell cycle arrest [35–37], is
strong in non-proliferating cells. Thus, this inhibitor plays important
role in the regulation of both quiescence and G1 progression. Reduced
expression of p27Kip1 is known as an independent prognostic marker
in a large variety of cancers, such as breast, prostate, colon, and gastric
carcinomas, and is associated with unfavorable prognosis [38]. Our
data demonstrate that PTH increases the levels of p27Kip1 in Caco-2
cells, but not the levels of p21Cip1, p16/INK4A and p15/INK4B
suggesting that PTH-induced G0/G1 arrest is mediated by p27Kip1. In
agreement with our results, Onishi and Hruska [27] showed that, in
UMR 106–01 osteoblastic cells, PTH inhibits the progression of cell
cycle from G1 to S phase by increasing the expression of p27Kip.
Mitogen-activated protein kinases (MAPKs) are commonly divided
into subfamilies that include the extra-cellular regulated protein
kinases (ERKs), the c-jun N-terminal kinases (JNKs), the p38, and the
Big MAP kinases (BMKs) [39]. JNKs are activated in response to
inﬂammatory cytokines, environmental stresses, such as UV radiation,
osmotic andheat shock, andDNAandprotein synthesis inhibition [40].
JNK activation has been implicated in the inhibition of Caco-2 cell
proliferation by R- and S-ﬂurbiprofen [20], whereas sulforaphane and
erucin, that induced G2/M arrest and cell death of these cells, activate
ERK1/2 but had no effect on JNK and p38 activation [41]. The present
study excludes, at least under our experimental conditions, the
involvement of JNK on PTH-induced Caco-2 cell cycle arrest. Further
studies are necessary to evaluate whether PTH employs p38 and
ERK1/2 pathways to regulate cell cycle progression.
Protein phosphatase 2A (PP2A) is an abundant and ubiquitous Ser/
Thr phosphatase with pleiotropic functions [42]. Kim S.W. et al.
[43,44] showed that induction of cell cycle arrest by ceramide and by a
synthetic trans-stilbene analog is regulated by PP2A-dependent Akt
dephosphorylation in PC-3 prostate cancer cells. In the intestinal cell
line IEC-18 it has been shown [21] that the down-regulation of cyclin
D1 was mediated by PP2A. However, we found that PP2A did not
participate in PTH regulation of cyclin D1 levels neither in the
expression of cyclin D3 and CDK6.
PKC constitutes a family of serine-threonine kinases, which are
classiﬁed into three major groups based on their structure and
activation mechanisms, and contains 11 isoforms encoded by 10
genes: conventional (α, βI, βII, γ), novel (δ, ε, η, θ, μ), and atypical
(ζ, λ) [45]. PKC plays a crucial role in signal transductions related with
cell proliferation [46], apoptosis [47], cell differentiation [48], and
hormone release [49]. Moreover, recent evidence found that PKCs can
impact on the cell cycle in either a positive or negative way,
depending on the cell type and isozyme speciﬁcity [50]. Indeed,
PKCs have been shown to regulate the progression of cells from G1 to
S phase as well as the transition from G2 to M phase, although the
underlying molecular mechanisms remain unclear [23]. Alterations in
the biochemical activity and expression of a number of PKCs have
been implicated in the malignant transformation process of several
organs, including the colon, in both humans and experimental
animals. Studies have also shown that human colon tumors may
Fig. 4. Effects of SP600125, Okadaic Acid and Calyculin A on the expression of cell cycle regulatory proteins. Caco-2 cells were pre-incubated for 30 min with SP600125 (20 μM), an
inhibitor of JNK, with Okadaic Acid (OA, 1 nM) or with Calyculin A (3 nM), inhibitors of PP2A, and then exposed to PTH (10−8 M, in DMEM 2% FBS) for 6 h followed byWestern blot
analysis of proteins from cell lysates using anti-cyclin D1 antibody, anti-cyclin D3 or anti-CDK6 antibodies. Blotted membranes were re-probed with anti-β-actin antibody. A
representative immunoblot (A) and the quantiﬁcation by scanning densitometry (B) of three independent experiments are shown; means±SD are given. *Pb0.025; **Pb0.01 with
respect to the control.
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Fig. 5. Downregulation of cyclin D1, cyclin D3 and CDK6 by PTH is PKC-dependent. Caco-2 cells were pretreated for 30 min with PKC inhibitors, Ro-31-8220 (200 nM), BIM (5 μM) or
chelerythine (2 μM) and then were exposed to PTH (10-8 M, in DMEM 2% FBS) for 6 h followed by Western blot analysis of protein from cell lysates using anti-cyclin D1 antibody,
anti-cyclin D3 or anti-CDK6 antibodies. Blotted membranes were re-probed with anti-β-actin antibody. A representative immunoblot (A) and the quantiﬁcation by scanning
densitometry (B) of three independent experiments are shown; means±SD are given. *Pb0.025, **Pb0.01 with respect to the corresponding control.
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Fig. 6. Upregulation of p27Kip1 by PTH is PKC-dependent. Caco-2 cells were pretreated for 30 min with PKC inhibitors, Ro-31-8220 (200 nM), BIM (5 μM) or chelerythine (2 μM)
followed by exposition to PTH (10-8 M, in DMEM 2% FBS) for 24 h. Proteins from cell lysates were immunoblotted with anti-p27Kip1 antibody. In order to evaluate the equivalence of
protein content among the different experimental conditions, blotted membranes were reprobed with anti-β-actin antibody. A representative immunoblot (A) and the
quantiﬁcation by scanning densitometry (B) of three independent experiments are shown; means±SD are given. *Pb0.025 with respect to the corresponding control.
1756 N. Calvo et al. / Biochimica et Biophysica Acta 1813 (2011) 1749–1757have a decrease in the protein expression of several speciﬁc PKC
isoforms, including PKC-α [51,52]. Moreover, PKC activation can
initiate a speciﬁc program of molecular events associated with cell
cycle withdrawal into G0 or a G0-like state in IEC-18 intestinal crypt
cells by downregulation of D-type cyclins and induction of p21Cip1
and 27Kip1 [53].
This study shows that, in Caco-2 cells, the inhibition of PKC up-
regulated the levels of cyclin D1, cyclin D3 and CDK6 but down-
regulated p27Kip1 protein level indicating that PTH regulates the
expression of these proteins through a PKC-dependent pathway. The
precise series of molecular events underlying PKC-mediated cell cycle
arrest remains to be investigated.
In conclusion, our results suggest that PTH changes the expression
of proteins involved in cell cycle regulation by activating the PKC
signaling pathway and induces G0/G1 phase arrest of human colon
Caco-2 cells.
Acknowledgments
This work was supported by grants from the Agencia Nacional de
Promoción Cientíﬁca y Tecnológica (ANPCYT), Consejo Nacional de
Investigaciones Cientíﬁcas y Técnicas (CONICET) and Universidad
Nacional del Sur, Argentina. We thank Gaston Stockman for kindly
providing assistance with the ﬂow cytometer.
References
[1] C.J. Sherr, G1 phase progression: cycling on cue, Cell 79 (1994) 551–555.
[2] T. Hirama, H.P. Koefﬂer, Role of the cyclin-dependent kinase inhibitors in the
development of cancer, Blood 86 (1995) 841–854.
[3] A. Besson, S.F. Dowdy, J.M. Roberts, CDK inhibitors: cell cycle regulators and
beyond, Dev. Cell 14 (2008) 159–169.
[4] J.T. Potts Jr., T.J. Gardella, H. Juppner, H.M. Kronenberg, Structure based design of
parathyroid hormone analogs, J. Endocrinol. 154 (1997) S15–S21.
[5] S.J. Silverberg, E. Shane, T.P. Jacobs, E. Siris, J.P. Bilezikian, A 10-year prospective
study of primary hyperparathyroidism with or without parathyroid surgery,
N. Engl. J. Med. 341 (1999) 1249–1255.
[6] R.C. Gensure, T.J. Gardella, H. Juppner, Parathyroid hormone and parathyroid
hormone-related peptide, and their receptors, Biochem. Biophys. Res. Commun.
328 (2005) 666–678.[7] T.M. Murray, L.G. Rao, P. Divieti, F.R. Bringhurst, Parathyroid hormone secretion
and action: evidence for discrete receptors for the carboxylterminal region and
related biological actions of carboxyl- terminal ligands, Endocrinology 26 (2005)
78–113.
[8] P. Urena, X.F. Kong, A.B. Abou-Samra, H. Juppner, H.M. Kronenberg, J.T. Potts Jr.,
G.V. Segre, Parathyroid hormone (PTH)/PTH-related peptide receptor messenger
ribonucleic acids are widely distributed in rat tissues, Endocrinology 133 (1993)
617–623.
[9] C. Gentili, S. Morelli, A. Russo de Boland, Characterization of PTH/PTHrP receptor
in rat duodenum: effects of ageing, J. Cell. Biochem. 88 (2003) 1157–1167.
[10] N. Calvo, O. German, A.R. de Boland, C. Gentili, Pro-apoptotic effects of parathyroid
hormone in intestinal cells, Biochem. Cell Biol. 87 (2) (2009) 389–400.
[11] A. Fujimori, S. Chang, L.V. Avioli, R. Civitelli, Structure-function relationship of
parathyroid hormone: activation of phospholipase-C, protein kinase-A and -C in
osteosarcoma cells, Endocrinology 130 (1992) 29–36.
[12] N.C. Partridge, B.E. Kemp, M.C. Veroni, T.J. Martin, Activation of adenosine 3′,5′-
monophosphate-dependent protein kinase in normal and malignant bone cells by
parathyroid hormone, prostaglandin E2, and prostacyclin, Endocrinology 108
(1981) 205–225.
[13] R. Civitelli, I.R. Reid, S. Westbrook, L.V. Avioli, K.A. Hruska, Parathyroid hormone
elevates inositol polyphosphates and diacylglycerol in a rat osteoblast-like cell
line, Am. J. Physiol. 255 (1988) E660–E667.
[14] N.S. Datta, G.J. Pettway, C. Chen, A.J. Koh, L.K. McCauley, Cyclin D1 as a target for
the proliferative effects of PTH and PTHrP in early osteoblastic cells, J. Bone Miner.
Res. 22 (7) (2007) 951–964.
[15] L. Qin, X. Li, J.K. Ko, N.C. Partridge, Parathyroid hormone uses multiple
mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to
S phase, J. Biol. Chem. 280 (4) (2005) 3104–3111.
[16] N.G. Calvo, C.R. Gentili, A.R. de Boland, The early phase of programmed cell death in
Caco-2 intestinal cells exposed to PTH, J. Cell. Biochem. 105 (4) (2008) 989–997.
[17] M. Bradford, A rapid and sensitive method for quantiﬁcation of microgram
quantities of proteins utilizing the principle of protein binding, Anal. Biochem. 72
(1976) 248–254.
[18] T.G. Cross, G. Scheel-Toellner, N.V. Neriquez, E. Deacon, M. Salmon, J.M. Lord,
Serine/threonine protein kinases and apoptosis, Exp. Cell Res. 256 (2000) 34–41.
[19] C. Tournier, P. Hess, D.D. Yang, J. Xu, T.K. Turner, A. Nimnual, D. Bar-Sagi, S.N.
Jones, R.A. Flavell, R.J. Davis, Requirement of JNK for stress-induced activation of
the cytochrome c-mediated death pathway, Science 288 (2000) 870–874.
[20] S. Grösch, I. Tegeder, K. Schilling, T. Maier, E. Niederberger, G. Geisslinger,
Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle
arrest in human colon carcinoma cells caused by ﬂurbiprofen enantiomers, FASEB
J. 17 (10) (2003) 1316–1318.
[21] L. Guan, K. Song, M.A. Pysz, K.J. Curry, A.A. Hizli, D. Danielpour, A. Black, J.D. Black,
Protein kinase C-mediated down-regulation of Cyclin D1 involves activation of
the translational repressor 4E-BP1 via a phosphoinositide 3-kinase/Akt-indepen-
dent, protein phosphatase 2A-dependent mechanism in intestinal epithelial cells,
J. Biol. Chem. 282 (19) (2007) 14213–14225.
[22] N. Calvo, A. Russo de Boland, C. Gentili, PTH inactivates the Akt survival pathway
in the colonic cell line Caco-2, Biochim. Biophys. Acta-MCR 1803 (2010) 343–351.
1757N. Calvo et al. / Biochimica et Biophysica Acta 1813 (2011) 1749–1757[23] D.D. Fishman, S. Segal, E. Livneh, The role of protein kinase C in G1 and G2/M
phases of the cell cycle (review), Int. J. Oncol. 12 (1988) 181–186.
[24] J.D. Black, Protein kinase C-mediated regulation of the cell cycle, Front. Biosci. 5
(2000) D406–D423.
[25] R.D. Finkelman, S. Mohan, T.A. Linkhart, S.M. Abraham, J.P. Boussy, D.J. Baylink,
PTH stimulates the proliferation of TE-85 human osteosarcoma cells by a
mechanism not involving either increased cAMP or increased secretion of IGF-I,
IGF-II or TGF-b, Bone Miner. 16 (1992) 89–100.
[26] F. Beier, P. LuValle, The cyclin D1 and cyclin A genes are targets of activated PTH/
PTHrP receptors in Jansen's metaphyseal chondrodysplasia, Mol. Endocrinol. 16
(9) (2002) 2163–2173.
[27] T. Onishi, K. Hruska, Expression of p27Kip1 in osteoblast-like cells during
differentiation with parathyroid hormone, Endocrinology 138 (5) (1997)
1995–2004.
[28] A. Devault, J.C. Cavadore, D. Fesquet, J.C. Labbé, T. Lorca, A. Picard, U. Strausfeld, M.
Dorée, Concerted roles of cyclin A, cdc25+ mitotic inducer, and type 2A
phosphatase in activating the cyclin B/cdc2 protein kinase at the G2/M phase
transition, Cold Spring Harb. Symp. Quant. Biol. 56 (1991) 503–513.
[29] S. van den Heuvel, E. Harlow, Distinct roles for cyclin-dependent kinases in cell
cycle control, Science 262 (1993) 2050–2054.
[30] C.J. Sherr, J.M. Roberts, Living with or without cyclins and cyclin-dependent
kinases, Genes Dev. 18 (2004) 2699–2711.
[31] C.J. Sherr, Cancer cell cycles, Science 274 (1996) 1672–1677.
[32] G.V. Thomas, K. Szigeti, M. Murphy, G. Draetta, M. Pagano, M. Loda, Down-
regulation of p27 is associated with development of colorectal adenocarcinoma
metastases, Am. J. Pathol. 153 (3) (1998) 681–687.
[33] R.V. Lloyd, L.A. Erickson, L. Jin, E. Kulig, X. Qian, J.C. Cheville, B.W. Scheithauer,
p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic
signiﬁcance in human cancers, Am. J. Pathol. 154 (2) (1999) 313–323.
[34] R. Palmqvist, R. Stenling, A. Oberg, G. Landberg, Prognostic signiﬁcance of p27
(Kip1) expression in colorectal cancer: a clinico-pathological characterization,
J. Pathol. 188 (1) (1999) 18–23.
[35] J. Nourse, E. Firpo, M. Flanagan, M. Meyerson, K. Polyak, M.H. Lee, J. Massague,
G. Crabtree, J. Robert, IL-2 mediated elimination of the p27Kip1 cyclin-Cdk
kinase inhibitor prevented by rapamicin, Nature 372 (1994) 570–573.
[36] S. Coast, W.N. Flanagan, J. Nourse, J. Roberts, Requirement of p27Kip1 for
restriction point control of the ﬁbroblast cell cycle, Science 272 (1996) 877–880.
[37] C.K.W. Watts, A. Brady, B. Sarcevic, A. deFazio, E.A. Musgrove, R.L. Sutherland,
Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated
with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma
protein phosphorylation, Mol. Endocrinol. 9 (1995) 1804–1813.
[38] W. Li, A. Sanki, R.Z. Karim, J.F. Thompson, C. Soon Lee, L. Zhuang, et al., The role of
cell cycle regulatory proteins in the pathogenesis of melanoma, Pathology 38
(2006) 287–301.[39] J.M. Kyriakis, J. Avruch, Mammalian mitogen-activated protein kinase signal
transduction pathways activated by stress and inﬂammation, Physiol. Rev. 81
(2001) 807–869.
[40] Y. Ip, R. Davis, Signal transduction by the c-Jun N-terminal kinase (JNK) from
inﬂammation to development, Curr. Opin. Cell Biol. 10 (1998) 205–219.
[41] J. Jakubíková, J. Sedlák, R. Mithen, Y. Bao, Role of PI3K/Akt and MEK/ERK signaling
pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2
transcription, G2/M arrest and cell death in Caco-2 cells, Biochem. Pharmacol. 69
(11) (2005) 1543–1552.
[42] V. Janssens, J. Goris, Protein phosphatase 2A: a highly regulated family of serine/
threonine phosphatases implicated in cell growth and signaling, Biochem. J. 353
(2001) 417–439.
[43] S.W. Kim, H.K. Jung, M.Y. Kim MY, Induction of p27(kip1) by 2,4,3′,5′-
tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt
dephosphorylation in PC-3 prostate cancer cells, Arch. Pharm. Res. 31(9) (2008)
1187–1194.
[44] S.W. Kim,H.J. Kim, Y.J. Chun,M.Y. Kim, Ceramide produces apoptosis through induction
of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3
prostate cancer cells, J. Toxicol. Environ. Health A 73 (21–22) (2010) 1465–1476.
[45] J.W. Soh, Y.S. Lee, I.B.Weinstein, Effects of regulatory domains of speciﬁc isoforms of
protein kinase C on growth control and apoptosis inMCF-7 breast cancer cells, J. Exp.
Ther. Oncol. 3 (2003) 115–126.
[46] A. Basu, U. Sivaprasad, Protein kinase C epsilon makes the life and death decision,
Cell. Signal. 19 (2007) 1633–1642.
[47] K. Yoshida, PKCdelta signaling: mechanisms of DNA damage response and
apoptosis, Cell. Signal. 19 (2007) 892–901.
[48] Y.F. Lin, H.M. Lee, S.J. Leu, Y.H. Tsai, The essentiality of PKCalpha and PKCbeta (I)
translocation for CD14(+)monocyte differentiation towards macrophages and
dendritic cells, respectively, J. Cell. Biochem. 102 (2007) 429–441.
[49] J.C. Garrido-Gracía, C. Bellido, R. Aguilar, J.E. Sanchez-Criado, Protein kinase C
cross-talk with gonadotrope progesterone receptor is involved in GnRH-induced
LH secretion, J. Physiol. Biochem. 62 (2006) 35–42.
[50] J.L. Oliva, M.C. Caino, A.M. Senderowicz, M.G. Kazanietz, S-Phase-speciﬁc
activation of PKC alpha induces senescence in non-small cell lung cancer cells,
J. Biol. Chem. 283 (2008) 5466–5476.
[51] M. Kusunoki, Y. Sakanoue, T. Hatada, H. Yanagi, T. Yamamura, J. Utsunomiya,
Protein Kinase C activity in human colonie adenoma and colorectal carcinoma,
Cancer 69 (1992) 24–30.
[52] T.J.McGarrity, L.P. Peiffer, E.B.Neely, R.G. Palavarapu,W.Koltun, P. Parker,M.K.Howett,
Localization of protein kinase C α isoform expression in the human gastrointestinal
tract, Cell Growth Differ. 7 (1996) 953–959.
[53] M.R. Frey, J.A. Clark, O. Leontieva, J.M. Uronis, A.R. Black, J.D. Black, Protein kinase C
signalingmediates a program of cell cycle withdrawal in the intestinal epithelium,
J. Cell Biol. 151 (2000) 763–777.
